Nature Communications (Jun 2019)
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
- Pratiti Bandopadhayay,
- Federica Piccioni,
- Ryan O’Rourke,
- Patricia Ho,
- Elizabeth M. Gonzalez,
- Graham Buchan,
- Kenin Qian,
- Gabrielle Gionet,
- Emily Girard,
- Margo Coxon,
- Matthew G. Rees,
- Lisa Brenan,
- Frank Dubois,
- Ofer Shapira,
- Noah F. Greenwald,
- Melanie Pages,
- Amanda Balboni Iniguez,
- Brenton R. Paolella,
- Alice Meng,
- Claire Sinai,
- Giovanni Roti,
- Neekesh V. Dharia,
- Amanda Creech,
- Benjamin Tanenbaum,
- Prasidda Khadka,
- Adam Tracy,
- Hong L. Tiv,
- Andrew L. Hong,
- Shannon Coy,
- Rumana Rashid,
- Jia-Ren Lin,
- Glenn S. Cowley,
- Fred C. Lam,
- Amy Goodale,
- Yenarae Lee,
- Kathleen Schoolcraft,
- Francisca Vazquez,
- William C. Hahn,
- Aviad Tsherniak,
- James E. Bradner,
- Michael B. Yaffe,
- Till Milde,
- Stefan M. Pfister,
- Jun Qi,
- Monica Schenone,
- Steven A. Carr,
- Keith L. Ligon,
- Mark W. Kieran,
- Sandro Santagata,
- James M. Olson,
- Prafulla C. Gokhale,
- Jacob D. Jaffe,
- David E. Root,
- Kimberly Stegmaier,
- Cory M. Johannessen,
- Rameen Beroukhim
Affiliations
- Pratiti Bandopadhayay
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Federica Piccioni
- Broad Institute of MIT and Harvard
- Ryan O’Rourke
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Patricia Ho
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Elizabeth M. Gonzalez
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Graham Buchan
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Kenin Qian
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Gabrielle Gionet
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Emily Girard
- Clinical Research Division, Fred Hutchinson Cancer Research Center
- Margo Coxon
- Clinical Research Division, Fred Hutchinson Cancer Research Center
- Matthew G. Rees
- Broad Institute of MIT and Harvard
- Lisa Brenan
- Broad Institute of MIT and Harvard
- Frank Dubois
- Broad Institute of MIT and Harvard
- Ofer Shapira
- Broad Institute of MIT and Harvard
- Noah F. Greenwald
- Broad Institute of MIT and Harvard
- Melanie Pages
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Amanda Balboni Iniguez
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Brenton R. Paolella
- Broad Institute of MIT and Harvard
- Alice Meng
- Division of Medical Oncology, Dana-Farber Cancer Institute
- Claire Sinai
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Giovanni Roti
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Neekesh V. Dharia
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Amanda Creech
- Broad Institute of MIT and Harvard
- Benjamin Tanenbaum
- Broad Institute of MIT and Harvard
- Prasidda Khadka
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Adam Tracy
- Broad Institute of MIT and Harvard
- Hong L. Tiv
- Experimental Therapeutics Core and Belfer Center for Applied Cancer Science
- Andrew L. Hong
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Shannon Coy
- Department of Pathology, Brigham and Women’s Hospital
- Rumana Rashid
- Department of Pathology, Brigham and Women’s Hospital
- Jia-Ren Lin
- Laboratory of Systems Pharmacology, Harvard Medical School
- Glenn S. Cowley
- Broad Institute of MIT and Harvard
- Fred C. Lam
- Koch Institute for Integrative Cancer Research, MIT
- Amy Goodale
- Broad Institute of MIT and Harvard
- Yenarae Lee
- Broad Institute of MIT and Harvard
- Kathleen Schoolcraft
- Division of Medical Oncology, Dana-Farber Cancer Institute
- Francisca Vazquez
- Broad Institute of MIT and Harvard
- William C. Hahn
- Broad Institute of MIT and Harvard
- Aviad Tsherniak
- Broad Institute of MIT and Harvard
- James E. Bradner
- Broad Institute of MIT and Harvard
- Michael B. Yaffe
- Broad Institute of MIT and Harvard
- Till Milde
- Hopp Children’s Cancer Center Heidelberg (KiTZ)
- Stefan M. Pfister
- Hopp Children’s Cancer Center Heidelberg (KiTZ)
- Jun Qi
- Division of Cancer Biology, Dana-Farber Cancer Institute
- Monica Schenone
- Broad Institute of MIT and Harvard
- Steven A. Carr
- Broad Institute of MIT and Harvard
- Keith L. Ligon
- Broad Institute of MIT and Harvard
- Mark W. Kieran
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Sandro Santagata
- Division of Medical Oncology, Dana-Farber Cancer Institute
- James M. Olson
- Clinical Research Division, Fred Hutchinson Cancer Research Center
- Prafulla C. Gokhale
- Experimental Therapeutics Core and Belfer Center for Applied Cancer Science
- Jacob D. Jaffe
- Broad Institute of MIT and Harvard
- David E. Root
- Broad Institute of MIT and Harvard
- Kimberly Stegmaier
- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
- Cory M. Johannessen
- Broad Institute of MIT and Harvard
- Rameen Beroukhim
- Broad Institute of MIT and Harvard
- DOI
- https://doi.org/10.1038/s41467-019-10307-9
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 16
Abstract
BET-bromodomain inhibitors could be used to treat medulloblastoma tumors with Myc amplifications. Here, the authors show that both the response and resistance to BET inhibitors in mice is mediated by bHLH/homeobox transcription factors.
